Description
Created On: 2020-07-15
Record Count: 4
Primary Industries
- Drugs
- Disease
- DNA
- Antibody
- Cancer
- Immune
- Vaccine
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 239014
Licensed Products shall mean and include any and all protein or peptide based products or biological materials, including antibodies, or other processes and products in the Licensed Field, the making, using, selling or importing of which would, but for this Agreement, constitute an infringement of one or more Valid Claims of the Licensed Patents.
patents, commonly known as the CMV promoter patents, or Stinski patents, relating to the expression of recombinant proteins used in the manufacture of Aurexis.
Aurexis is currently being evaluated in a Phase II clinical trial as a first-line therapy, in combination with standard of care antibiotics, to treat serious, life-threatening Staphylococcus aureus, or S. aureus, bloodstream infections in hospitalized patients.
Staphylococcus aureus is a Gram-positive, round-shaped bacterium that is a member of the Firmicutes, and it is a usual member of the microbiota of the body, frequently found in the upper respiratory tract and on the skin.
IPSCIO Record ID: 239013
5,981,216 – Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
5,770,359 – Recombinant DNA sequences, vectors containing them and method for the use thereof
5,827,739 – Recombinant DNA sequences, vectors containing them and method for the use thereof
5,591,639 – Recombinant DNA expression vectors
5,658,759 – Recombinant DNA expression vectors
Product means a monoclonal antibody to a bacterial cell surface adhesion known as Aurexis(TM) of which Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the Materials, or any formulation containing the same.
Intellectual Property means Materials Know-How and Patent Rights owned by Licensor or an Affiliate of Licensor and which Licensor has a right to grant herein.
Patent Rights means the patents and applications which Licensor has a right to grant herein short particulars of which are set out hereto and all patents and applications thereof of any kind throughout the world whether national or regional including but without prejudice to the generality of the foregoing, author certificates, inventor certificates, improvement patents, utility certificates and models and certificates of addition and including any divisions, renewals, continuations, continuations in part, extensions of reissue thereof.
Intellectual property and materials relating to the expression of recombinant monoclonal antibodies to bacterial surface proteins for use in the manufacture of Aurexis.
IPSCIO Record ID: 239032
Licensed Products shall mean and include any and all biological materials and products and processes the making, having made, using, selling or importing of which would, but for this Agreement, constitute an infringement of one or more Valid Claims of the Licensed Patents.
Licensee uses advances in biological sciences to discover, develop, manufacture and market products that treat or prevent infectious diseases, immune system disorders and cancer.
IPSCIO Record ID: 238992
VIF means the molecule known as virulence inhibitory factor and related small molecule analogues.
Licensed Product means a product that utilizes or incorporates the Research Technology.
Research Technology means (a) all Information conceived of or reduced to practice by Licensor in the course of any work conducted pursuant to this Agreement, and (b) all Prior Research Technology.
Prior Research Technology means all Information conceived of or reduced to practice by Licensor in the course of any work conducted pursuant to the Prior Research Agreement.
Research Program means the research program related to RAF to be performed by Licensor hereunder.
Staphylococcus aureus is a Gram-positive, round-shaped bacterium that is a member of the Firmicutes, and it is a usual member of the microbiota of the body, frequently found in the upper respiratory tract and on the skin.
